Neurocrine Biosciences - 500 Beiträge pro Seite

[springmaus]

Guten Morgen,
wer hat Fakten, Meinungen oder sonst irgendwas
zu WKN 900964 ?
(...ist mittlerweile an der nasdaq)

www.neurocrine.com

hoffe auf viiiele Beiträge !

[Lachmann]

Hallo,

Neurocrine Biosciences forscht und entwickelt Produkte gegen Krankheiten des zentralen Nervensystems und des Immunsystems wie z.b. Krebs, Diabetes, Multiple Sklerose, Alzheimer, Insomina oder gegen Depressionen.

Neurocrine hat seine Sitz in San Diego und 150 Angestellte. Es sind einige aussichtsreiche Produkte in der Pipeline, vier davon am Ende d. Phase II. Kooperationen bestehen u.a. mit Wyeth Ayers, Novartis, Eli Lilly und Janssen. Dabei hat Neurocrine schon einiges an s.g. Meilenstein-payments erhalten!

NASDAQ - Kürzel NBIX
Bewertet wird NBIX von 4 Analysten -> 2x strong buy / 2x buy

Umsatz 99: 16,8 Millionen
Verlust 99: 16,8 Millionen oder -0,88$/Aktie

NBIX hat jedoch 92,6 Mll. rein an Cash für die weitere Entwicklung zur Verfügung!

Dass die Produkte aussichtsreich erscheinen zeigen die Erwartungen für die Zukunft:
estimates 2000: Verlust -0,63$/Aktie
estimates 2001: Verlust -0,71$/Aktie
estimates 2002: Gewinn +1,21$/Aktie

NBIX wird zur Zeit mit 667,9 Mll. $ bewertet.

Ich halte die Aktie für sehr aussichtsreich, mit dem Cashbestand besteht einiges an Luft.

Wenn die Gewinnprognosen für 2002 halbwegs eintreten bzw. bis dahin keine Rückschläge auftreten, sehe ich NIBIX auf Sicht von 18 Monaten mit einen Wert von 3,5 Mrd. fair bewertet!

Gruß
Lachmann

[springmaus]

Hallo Lachmann,
sehr informativer Beitrag (scheint aus der Homepage zu sein),
schade dass sich kaum einer für so eine interessante Aktie
interessiert (noch !!!).
Akt. 40 € und wird wohl in den nächsten Wochen die 100 € erreichen.
Freue mich schon!

[springmaus]

...übrigens auch im DWS-Biotech-Aktien Typ 0 enthalten.

[Kephas]

Hallo zusammen,
hat keiner eine aktuelle Stellungnahme zu
diesem Wert????
Wäre echt glücklich darüber.
Danke,im voraus!!!!
Kephas

[Geko007]

Hallo Leute!
Neurocrine ist in einem super Segment tätig!Ich wollte noch sagen das BB Biotech über 1 Milion Aktien hält,und das war für mich ein Zeichen sich bei 18 mit der Aktie einzudecken.Natürlich konnen die Kurse noch unter druck kommen , aber wenn die Super Produkte aus der Phase lll zugellase werden dann ...
MFG Geko

[Geko007]

Noch eine Info aus der BB Biotech Homapage:Neurocrine ist eine der führenden Neurobiologiefirmen. Ein Produkt zur Behandlung von Hirntumoren ist in Phase III. Zwei weitere Produkte sind in Phase II, darunter ein Schlafmittel mit einem potentiell besseren Profil im Vergleich zu den heute erhältlichen Medikamenten. Grosse Erwartungen werden in ein Medikament zur Behandlung von Depression mit einem völlig neuartigen Wirkprinzip (CRF antagonist) gesetzt.
MFG Geko

[Geko007]

Endlich eine Erholung!
MFG Geko

[mr.lukoil]

Hallo neurocriner,

gab heute auf der nasdaq-news-Seite eine Meldung, nach der sich ein von Neurocrine entwickeltes Protein (?) in den klinischen Testphasen I und II als sehr wirksam erwiesen haben soll. WWW.nasdaq.com, Kuerzel nbix, news button.

Immerhin mal wieder ein solider Anstieg, der ein wenig beruhigt.

Gruesse

lukoil

[FHD]

Haaalllloooo!! Ist hier noch jemand?

[MrGruendlich]

Hallo Boardler!!!!!
Neurocrine Biosciences (ticker: NBIX, exchange: NASDAQ) News Release - Tuesday, June 06, 2000


--------------------------------------------------------------------------------
Neurocrine Biosciences Inc. Announces Advancement of Research Program in Obesity and Diabetes; Program Awarded National Institutes of Health Grant

SAN DIEGO--(BW HealthWire)--June 6, 2000--Neurocrine Biosciences Inc. (Nasdaq:NBIX) announced today that the company has achieved early milestones in its Melanocortin receptor research program in obesity and diabetes and has advanced this project to program status.

This coincides with an award from the NIH of a Phase I grant supporting Neurocrine`s research and development efforts on Melanocortin receptor research. Neurocrine`s most advanced drug discovery program within the MCR area is the development of orally active and selective agonists of Melanocortin Receptor 4 (MCR4). Agents which activate the MCR4 are expected to be useful for indications where regulation of melanocortin responsive components in the central nervous system is beneficial, such as regulation of body weight and diabetes.

Neurocrine holds patent positions on MCRs 1-5 through exclusive and non-exclusive patent licenses as part of its acquisition of Northwest Neurologic (NNL). Dr. Roger Cone, co-founder of NNL and Professor at the Vollum Institute of the Oregon Health Sciences University was one of the first groups to clone the human forms of the melanocortin receptors and has played a leading role in the characterization of the function of melanocortins in the central nervous system.

The overall goal of the program is to develop orally active and selective agonists of MCR4. Neurocrine scientists have used human MCR4 binding and secondary messenger assays in high throughput screens to identify a set of small molecule MCR4 agonists with modest potency and efficacy. In the Phase I grant high throughput parallel synthesis, in combination with intuitive medicinal chemistry and computational chemistry ("multi-channel" technology), will be used to optimize several compound families and develop lead molecules with higher potency. The activity of these agonists will then be evaluated against the full panel of MCRs to construct a selectivity profile. With several compounds identified in the primary screens, the company expects the improvements generated by these technologies will lead to compounds having the desired profile to be considered development candidates.

"The MC-4 receptor agonist program extends the company`s small molecule expertise into another type of small molecule drug, one that mimics the natural ligand," said Dr. Roger Cone. "Neurocrine researchers have repeatedly demonstrated their ability to develop G-protein coupled receptors (GPCR) ligands that show promise for the treatment of a number of disorders," said Cone.

Neurocrine scientists, led by co-project leaders Dr. Val Goodfellow and Steve Kurtz, using the company`s "multi-channel" approach described above, have rapidly developed several families of small molecule agonists with improved affinity for the human receptor. "The MCR4 program capitalizes on Neurocrine`s GPCR platform and the power of the integrated research and development approach underlying Neurocrine`s programs. We feel that receipt of the NIH award provides peer review validation of the program as well as funding through outside sources," said Paul J. Conlon, vice president Discovery Research. "We expect to bring a small molecule MCR4 agonist compound into preclinical development during 2001."

Neurocrine Biosciences is a leading neuroscience company focused on the discovery and development of novel therapeutics for neuropsychiatric, neuroinflammatory and neurodegenerative diseases and disorders. The company`s neuroscience, endocrine and immunology disciplines provide a unique biological understanding of the molecular interaction between central nervous, immune and endocrine systems for the development of therapeutic interventions for anxiety, depression, insomnia, stroke, malignant brain tumors, multiple sclerosis, obesity and diabetes.

Neurocrine Biosciences Inc. news releases are available through the company`s Web site via the Internet at http://www.neurocrine.com.

In addition to historical facts, this press release may contain forward-looking statements that involve a number of risks and uncertainties. Among the factors that could cause actual results to differ materially from those indicated in the forward looking statements are risks and uncertainties associated with Neurocrine`s research and development programs and business and finances including, but not limited to, risks and uncertainties associated with, or arising out of, drug discovery, pre-clinical and clinical development of products including risk that research may not generate development candidates, development candidates will not successfully proceed through early clinical trials or that in later stage clinical trials will not show that they are effective in treating humans; determinations by regulatory and governmental authorities; changes in relationships with strategic partners and dependence upon strategic partners for performance of clinical and commercialization activities under collaborative agreements including potential for any collaboration agreement to be terminated without any product success; uncertainties relating to patent protection and intellectual property rights of third parties; impact of competitive products and technological changes; availability of capital and cost of capital; and other material risks. A more complete description of these risks can be found in the company`s Form 10K for Dec. 31, 1998. Neurocrine undertakes no obligation to update the statements contained in this press release after the date hereof.


CONTACT: Neurocrine Biosciences Inc.

Claudia Jones or Paul Hawran, 858/658-7600